Designed with full walk-away capability and specifically for low- throughput labs, the DS2 represents a major leap forward in electro-mechanics and software design. Reliable, cost-effective, and easy to use and maintain, the DS2 packs full automation power in the smallest footprint available. The system quickly and easily processes two 96-well microplates and up to 12 different assays simultaneously and features the most user-friendly control system available, chain of custody, and instrument diagnostics. An open system, the DS2 delivers sample-in / results-out automation of virtually any ELISA microplate assay. Feature-rich and groundbreaking in its process simulation and ease of use, the DS-Matrix software allows any lab technician to use the DS2 with minimal training, so labs new to automation can rapidly integrate the system with confidence to begin delivering better, more-reliable results.
LeadCare II is an improved version of ESA's original LeadCare system, the most-widely used blood-lead-testing system worldwide. LeadCare II removes all the complications formerly associated with blood-lead testing -- waiting days for expensive lab results, or spending precious time trying to contact patients for critical follow-up care. The system delivers quantitative blood- lead results, equivalent to those reported by reference laboratories, with only two drops of blood in just three minutes. It is far-simpler to administer than traditional blood-lead tests. It requires only a finger-stick sample, can be combined with other routine waived blood tests, and saves administrative time spent on paper work, tracking, and follow-up. Further, since LeadCare II qualifies for reimbursement as a quantitative blood-lead test and the cost per test is actually less than one would pay an outside laboratory, it frees valuable resources to enable individual physicians and lead-poisoning-prevention programs to screen more at-risk children.
"LeadCare II and DS2 are important examples of Magellan's focus on developing new diagnostic products that serve critical unmet needs in the marketplace and improve clinical outcomes," said Magellan President and Chief Executive Officer Robert J. Rosenthal, PhD. "The trend in medicine today is to move testing closer to the patient so clinicians have more control and faster access to results. Studies show that this approach works: it enables speedier, more-accurate diagnoses, allowing clinicians to make better healthcare decisions -- initiate treatment as soon as possible when required, and offer peace of mind when it's not."
ESA will also feature HPLC systems for clinical diagnostics (Plasma Metanephrines, Urine Metanephrines, Urine VMA, 5HIAA and HVA). Its HPLC oncology systems, including the only FDA-cleared system for plasma metanephrine, have been adopted by major clinical laboratories throughout the world to rule out potentially fatal chromaffin cell tumors -- usually found in the adrenal glands -- with far more sensitivity than traditional assays. ESA's HPLC systems for esoteric clinical applications are optimized for cutting-edge research on a wide variety of subjects critical to health and well-being -- from Co enzyme Q 10 and the study of fat-soluble vitamins, to the study of xenoestrogens (compounds found in everyday items, such as food and drink packages that mimic the effects of endogenous estrogens).
Dynex will also demonstrate its four-plate DSX(TM) automated ELISA processing system, a flexible, open system with full walk-away capability -- now the standard worldwide for medium-throughput labs, and the TRIAD(TM) multimode microplate reader, with three detection modes (fluorescence, luminescence, and absorbance) in one instrument.
About Magellan Biosciences
Magellan Biosciences develops point-of-care products, related consumables, and automated laboratory systems for clinical diagnostics and biomedical research worldwide. These tools enable scientists and clinicians to produce better, more-reliable results. And improved results help drive better outcomes: a new understanding of health and disease, earlier, more-accurate diagnoses -- breakthrough discoveries that can lead to novel treatments, new cures -- innovations to enhance life. Magellan serves customers through its wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel. For more information, visit http://www.magellanbio.com.
About Dynex Technologies
The Experts in Microplate Analysis, Dynex Technologies, Inc. is a leading manufacturer of microplate instrumentation incorporating advanced detection and fully automated sample handling, consumables, and accessories used in clinical diagnostics, drug discovery, biomedical research, and industrial applications worldwide. Founded in 1952, and headquartered in Chantilly, Virginia, Dynex is a wholly owned subsidiary of Magellan Biosciences.
About ESA Biosciences
ESA Biosciences, Inc. enables answers to pressing applications challenges by applying its expertise in specialty detection and electrochemistry, combined with components, kits, and reagents, for analytical laboratories, commercial diagnostics laboratories, and the clinical point-of-care setting. Founded in 1968, ESA is a wholly owned subsidiary of Magellan Biosciences, Inc.
Source: Magellan Biosciences, Inc.
